A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Status:
Recruiting
Trial end date:
2022-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new
formulation), and if it can be safely combined with Spartalizumab and to determine the
appropriate dose and schedule for further study. Moreover, the study will characterize the
pharmacokinetic profiles of NIZ985 as a single agent and in combination with Spartalizumab
and identify preliminary anti-tumor activity.